医药生物行业周报：心血管疾病高发，Lp（a）或成为降脂治疗新靶点

Investment Rating - The report assigns a "Buy" rating for the industry, indicating an expected performance that will exceed the market by over 20% [50]. Core Insights - The report highlights the increasing prevalence of cardiovascular diseases (CVD) and the potential for Lp(a) to become a new target for lipid-lowering therapy, with multiple companies actively developing Lp(a) inhibitors [57][58]. - The cardiovascular medication market in China reached 27.3 billion yuan in 2023, with a projected 14.7 billion yuan in the first half of 2024, indicating significant growth potential [12]. - The report emphasizes the rapid growth of PCSK9 inhibitors, which have become a key player in the lipid-lowering market, alongside traditional statins [12][31]. Summary by Sections Section 1: Cardiovascular Disease and Treatment Landscape - CVD remains the leading cause of death in urban and rural populations, accounting for approximately 48.98% and 47.35% of deaths respectively [30]. - The prevalence of dyslipidemia among adults aged 18 and older was reported at 35.6% in 2018, showing a continuous increase since 2015 [30]. Section 2: Lipid-Lowering Medications - The report categorizes lipid-lowering medications into statins, cholesterol absorption inhibitors, and PCSK9 inhibitors, with statins accounting for 68% of sales in the cardiovascular medication market [12][31]. - New lipid-lowering drugs targeting Lp(a) are under development, with several candidates entering phase III clinical trials [58]. Section 3: Market Performance - The pharmaceutical and biotechnology sector experienced a decline of 2.13%, underperforming the CSI 300 index by 1.99 percentage points, ranking 13th among 31 sub-industries [7][22]. - Among sub-sectors, traditional Chinese medicine showed the smallest decline at 0.55%, while the raw materials sector faced the largest drop at 3.67% [60]. Section 4: Investment Recommendations - The report recommends several companies as potential beneficiaries in the lipid-lowering market, including Jingxin Pharmaceutical and Xinlitai, among others [21][28].